Heat Detection

This prospective observational study focuses on patients who experience out-of-hospital cardiac arrest OHCA. The study aims to monitor core body temperature using an esophageal probe during transport and upon arrival at the hospital. Researchers also observe environmental factors like ambient temperature and interventions used to prevent hypothermia during resuscitation based on European Resuscitation Council Guidelines 2015 or newer. When a patient meets inclusion criteria and CPR is established according to guidelines, an esophageal temperature probe is inserted on site during ongoing resuscitation efforts. Body temperature is measured on scene and again upon hospital arrival using the probe. Data on weather conditions, altitude, patient activity, and hypothermia protection such as clothing are also recorded throughout the process. Participants are monitored from the moment resuscitation begins until hospital arrival, with core temperature measured continuously. Additional data collected include environmental temperature at the site, time from cardiac arrest to return of spontaneous circulation ROSC, heart rhythm at arrival of advanced life support teams, and use of mechanical chest compression devices. The primary outcome is core temperature at hospital arrival, tracked over an average of one year during study completion.

Researchers are evaluating the use of local thermotherapy as a treatment to help control mild-to-moderate COVID-19, caused by the SARS-CoV-2 virus. This virus is a positive-sense single-stranded RNA virus responsible for a global pandemic with varying fatality rates. Raising the temperature on affected areas may inhibit viral replication by producing small interfering RNAs that block viral transcription. Thermotherapy has been previously used to target RNA viruses, cancer cells, and parasitic infections, which supports its potential use against COVID-19 to reduce viral load and aid the immune response. The study compares two groups one receiving usual hospital care plus an electric heat pad applied to the chest for 90 minutes twice daily over 5 days, and the other receiving usual hospital care alone. The heat pad raises the skin temperature to 40-42 0C, a range expected to facilitate virus elimination without causing discomfort. The electric cushion is a commercially available device widely used for muscle pain and arthritis treatment. Participants will undergo evaluations over 28 days to monitor disease progression and other health outcomes such as mortality, time to severe or critical COVID-19, hospitalization duration, oxygen requirement, and adverse events. Clinical status will be assessed using scales like the National Early Warning Score 2 NEWS-2, and safety and tolerance of the thermotherapy will be tracked. The trial is randomized and open-label, with follow-up visits occurring at multiple time points during and after the treatment period.

The trial investigates how wearing the hijab affects heat loss and body temperature during exercise in hot, dry conditions. It focuses on young healthy women performing moderate-intensity intermittent exercise at 40C with 15% humidity. The goal is to understand how the hijab influences dry and evaporative heat exchange during physical activity. Participants take part in two exercise sessions inside a controlled heat chamber. One session is done wearing a cotton t-shirt and shorts, and the other while wearing a hijab over the same clothing. Each session includes 30 minutes of resting in a thermoneutral environment, followed by two 30-minute moderate-intensity exercise bouts separated by a 15-minute rest, then a 60-minute recovery period. During the study, researchers measure various heat loss parameters, core and skin temperatures, heart rate, perceived exertion, and thermal and thirst sensations at the end of the exercise bouts. The study uses a randomized crossover design, and participants are monitored closely throughout. The total participation duration includes baseline resting, exercise, and recovery periods within each session.